Shopping Cart
Remove All
Your shopping cart is currently empty
Lifastuzumab vedotin is an antibody-drug conjugate (ADC) that blocks cell division by inhibiting tubulin polymerization, with potential applications in the research of non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC).

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $245 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $535 | 2-4 weeks | 2-4 weeks | |
| 10 mg | Preferential | 2-4 weeks | 2-4 weeks |
| Description | Lifastuzumab vedotin is an antibody-drug conjugate (ADC) that blocks cell division by inhibiting tubulin polymerization, with potential applications in the research of non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC). |
| Synonyms | RG-7599, NaPi2b-ADC, DNIB-0600A, DNIB0600A |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | MMAE |
| Gene ID | |
| Uniprot ID | |
| Target | NaPi2b/SLC34A2 |
| Cas No. | 1401812-88-1 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.